The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | DENIM: dendritic cell maintenance therapy in mesothelioma
Robin Cornelissen, MD, PhD, Erasmus University Medical Center, Rotterdam, The Netherlands, shares the details of the ongoing Phase III DENIM trial (NCT03610360) of dendritic cell (DC) maintenance therapy in malignant pleural mesothelioma (MPM). MPM is an aggressive cancer with poor survival rates with no effective therapies available for maintenance or following relapse. As DC therapy has been shown to induce tumor-specific CD8+ T-cell activity, a multicenter Phase III trial has been designed to investigate the therapy in MPM. Following first-line chemotherapy, patients will be randomized to receive DC therapy and best supportive care, or best supportive care alone. Overall survival will serve as the study’s primary endpoint, while safety, progression-free survival, overall response rate and quality of life will also be investigated. Enrollment in the trial is ongoing. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
